Polyethylene glycol loxenatide reduces NETosis and immunofluorescence hyperactivation in Behçet’s disease Authors: Fang Jia, Xiaoli Wu, Huiyang Sheng Published: 2025 ABSTRACT AbstractBackgroundNeutrophil hyperactivation, particularly through the release of neutrophil extracellular traps (NETosis), plays a crucial role in driving vascular inflammation in Behçet’s disease (BD). While pyroptosis has been linked to the pathogenesis of BD, the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on neutrophil dysregulation have not been previously explored.MethodsWe investigated the effects of polyethylene glycol loxenatide (PEX168) on neutrophil activation using neutrophils isolated from BD patients, LPS-stimulated neutrophils from healthy donors, and a murine model of BD. We employed a variety of techniques, including western blotting, flow cytometry for reactive oxygen species (ROS) detection, immunohistochemistry on oral mucosa, colon, and pericardial vessels, transmission electron microscopy for cellular ultrastructure, and immunofluorescence to evaluate NETosis, pyroptosis, and inflammasome activation.ResultsPEX168 significantly and dose-dependently reduced neutrophil hyperactivation, decreasing NETosis markers (CitH3, NE, MPO) and ROS. It preserved cellular ultrastructure by mitigating mitochondrial swelling and chromatin margination. While higher concentrations inhibited the NLRP3–caspase-1–IL-1β pathway, PEX168 did not induce pyroptosis, as uncleaved GSDMD-N’ remained nuclear. Low concentrations transiently enhanced IL-1β secretion, indicating biphasic immunomodulation via NF-κB.ConclusionPEX168 attenuates neutrophil hyperactivation and NETosis in Behçet’s disease via ROS suppression and upstream inflammasome regulation, disrupting inflammatory signaling without provoking pyroptosis. These findings support GLP-1 RAs as a targeted treatment for neutrophil-driven autoimmune disorders.Keywords: Neutrophil extracellular traps, Pyroptosis, Hyperactivation, Polyethylene glycol loxenatide, Behçet’s disease Introduction Behçet’s disease (BD) is a multisystem vasculitis characterized by a heterogeneous clinical presentation and disease course. Key manifestations include oral and genital ulcers, skin lesions such as papules and nodules, arthritis, uveitis, venous thrombosis, arterial aneurysms, premature neonatal birth, and hearing loss [1–3]. Although the exact pathogenesis remains unclear, current evidence indicates that dysregulated innate and adaptive immune responses play a central role, with prominent hyperactivation of neutrophils, T cells, and monocytes/macrophages contributing to acute and recurrent inflammation [4, 5]. Neutrophil hyperactivation in BD is associated with exaggerated inflammatory responses, including the release of cytotoxic granules, reactive oxygen species, and the formation of neutrophil extracellular traps (NETs) via NETosis, which is a unique form of programmed cell death distinct from apoptosis and necrosis [6, 7]. This process involves nuclear membrane disintegration, chromatin decondensation, and the mixing of granular enzymes such as myeloperoxidase and neutrophil elastase with extracellular DNA [8, 9]. Additionally, inflammasome-mediated pyroptosis is a highly inflammatory cell death process, which has been implicated in BD, particularly through activation of the NLRP3 inflammasome in neutrophils and other immune cells [10]. Together, NETosis and pyroptosis may exacerbate tissue damage and perpetuate the inflammatory cycle in BD. Current management of BD relies heavily on anti-inflammatory and immunosuppressive agents, including glucocorticoids, which are often associated with significant adverse effects and a high risk of relapse upon discontinuation [11, 12]. Thus, there is an urgent need for targeted therapies that modulate specific inflammatory pathways without broad immunosuppression. Polyethylene glycol loxenatide (PEX168) is a glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by Hansoh Pharmaceuticals (China; approval no. 86901444001007). Beyond its glucose-regulating effects, PEX168 has demonstrated anti-inflammatory properties in previous studies [13]. Given the central role of neutrophil dysregulation in BD, and emerging evidence that targeting neutrophil activation can improve outcomes in chronic inflammatory diseases [14, 15], we hypothesized that PEX168 may offer therapeutic benefits in BD by suppressing neutrophil hyperactivation, NETosis, and pyroptosis, thereby reducing epithelial injury and disease severity. Therefore, in this study, we aimed to evaluate the novel GLP-1 receptor agonist PEX168 as a potential therapeutic strategy for BD, investigating its efficacy in ameliorating BD symptoms by targeting neutrophil hyperactivation, suppressing associated NETosis and pyroptosis pathways, and mitigating resultant epithelial injury, thereby addressing the limitations of current therapies. Materials and methods Human neutrophil isolation and treatment Cell sorting Peripheral venous blood (10 mL) was collected from healthy donors and patients with Behçet’s disease (BD) between April 2021 and August 2023. All participants were between 23 and 74 years of age. The control donors were age-matched with the patients’ samples. This study was approved by the Ethics Committee of the Stomatological Hospital of Southern Medical University (Approval No: 2021A01923776). Whole blood samples were processed by adding 100 mL of 1 × red blood cell lysis buffer (Ecotop, China), followed by centrifugation at 300 × g for 6 min (Eppendorf, Germany). Neutrophils were then isolated through negative selection using the EasySep™ Direct Human Neutrophil Isolation Kit (StemCell, 19666, Canada), as illustrated in Fig. 1C. PEX168 reduces NETosis and improves cellular integrity in neutrophils from BD patients. A, B Expression of NETosis markers (PAD4, MPO, CitH3, NE, LDH) and extracellular dsDNA was elevated in BD neutrophils and significantly reduced by 6.4 ng/mL PEX168 (P = 0.000). C Neutrophil purity was 88.75% after RBC lysis and 96.58% after magnetic selection. D ROS production increased in BD neutrophils and decreased dose-dependently with PEX168 (P = 0.002); the 6.4 ng/mL group showed the lowest ROS level (P = 0.001). RNS remained unchanged (P = 0.665). Values represent the mean ± SD, n = 6. *P < 0.05, **P < 0.01 Cell identification The cell suspension was counted and 50 µL was aliquoted. Then, 100 µL of phosphate-buffered saline (PBS) and 2 µL each of anti-CD45-APC (Elabscience, E-AB-F1039E, China), anti-CD16-FITC (Elabscience, E-AB-F1005C, China), and anti-CD66b-PE (Elabscience, E-AB-F1267D, China) were added. After incubation at 4 °C for 45 min, the cells were centrifuged at 300 × g for 5 min. The supernatant was discarded, and the pellet was resuspended in HBSS (Gibco, 14025076, USA) for flow cytometry analysis (Cytoflex, BD, USA). Neutrophil activation and PEX168 treatment Neutrophils were isolated from peripheral venous blood of the BD patient. A concentration gradient of PEX168 (0.1 pM to 1 μM, 12 logarithmic points) was applied, covering 0.1 to 1000 times its clinical blood concentration (− 0.83 nM). Incubation durations were 2 h, 4 h, 8 h, and 16 h. Controls included blank (0.1% BSA-PBS) and positive control (0.2 nM secukinumab; MCE, HY-P9927, USA). Key endpoints were ROS production and IFN-γ/IL-17 ratio. IC₅₀/EC₅₀ analysis indicated effective inhibition of BD pathological pathways at 0.09–0.45 nM PEX168, below the clinical Cₘₐₓ (0.83 nM). Isolated neutrophils from BD patients and healthy donors were cultured in serum-free medium (X-VIVO 15, Lonza, 04-418Q, Switzerland). Healthy neutrophils were activated with 1 ng/mL LPS (Solabio, L8880, Source: Escherichia coli 055:B5, China) for 30 min at 37 °C under 5% CO₂. Based on dose–response results, PEX168 was tested at 0.8, 1.6, 3.2, and 6.4 ng/mL on both LPS-stimulated healthy neutrophils and BD patient neutrophils for 4 h (LPS + PEX168 and BD + PEX168 groups). A BD group received 30 ng/mL secukinumab (BD + 30Sec, positive control) for 4 h. Animal modeling and treatment A total of 35 female BALB/C mice (28 days old, SPF grade) were acclimatized for 7 days and then allocated to control, model, or treatment groups. All animals received two intracutaneous injections of 20 μL HSV-1 virus (KOS strain, ATCC VR-1493D; 1 × 10⁶ PFU/mL propagated in Vero cells), administered 10 days apart. From week 4 to 24 after the second inoculation, mice were monitored weekly for symptoms including oral and genital ulcers, arthritis, and intestinal lesions. Model validation was performed via HE staining of colon and knee joint tissues from one control and two model groups. Following successful model establishment, the negative control (NC) group remained untreated, while the model group continued normal feeding. Five treatment groups (n = 5 per group) received weekly subcutaneous injections of PEX168 at doses of 1, 2, 4, 8, or 12 μg/kg (injection volumes: 2–24 μL). Ethical compliance, tissue sampling and processing All procedures were approved by the Animal Ethical and Welfare Committee of GDMLAC (No: C202106-11) and performed in accordance with international guidelines. Mice were group-housed (≤ 5 per cage) under a 12 h light–dark cycle at 22 ± 2 °C and 50 ± 10% humidity with free access to food and water. After 7 days of acclimatization, grouping was performed. Mice were anesthetized using 5% isoflurane (RWD R500IP). Peripheral blood was collected via retro-orbital puncture using heparin-coated capillaries and transferred to EDTA-containing tubes. Neutrophils were isolated immediately using the EasySep™ Mouse Neutrophil Enrichment Kit (Stemcell, 19762, Canada). Animals were monitored daily; predefined humane endpoints included severe lethargy, unresponsiveness, respiratory distress, or hypothermia (< 37 °C). Euthanasia was performed by cervical dislocation under deep anesthesia. Tissue samples (cardiac vessels, oral mucosa, and colon) were collected, snap-frozen in liquid nitrogen, and stored at − 80 °C for further analysis. All procedures followed the “3R” principles to minimize animal use and suffering. Protein and molecular analyses Protein extraction and western blotting The treated neutrophils were collected. Tissue samples were ground using a frozen tissue grinder (Bionoon-24LD, China) and lysed with 50 µL RIPA buffer (Beyotime, P0013B, China) supplemented with 1 µL 50 × protease inhibitor (Roche, 11206893001, Switzerland) and 0.5 µL 100 × phosphatase inhibitor (GlpBio, GK10011, USA). The lysate was incubated on ice for 10 min, followed by centrifugation at 4 °C and 12,000 × g for 20 min. The supernatant was collected, and protein concentration was determined using the BCA Protein Assay Kit (Pierce™, 23227, USA). Proteins were separated by electrophoresis using the Bio-Rad system (Bio-Rad, USA) under the following conditions: 80 V for 30 min and then 120 V for 90 min. Subsequently, the proteins were transferred to a PVDF membrane at 250 mA for 100 min. The membrane was blocked with 5% bovine serum albumin (BSA) for 1 h at room temperature. Western blotting was performed using the following primary antibodies diluted in 5% BSA (Genview, FA016-100, USA) at ratios ranging from 1:2000 to 1:8000: anti-PAD4 (ab128086, UK),anti-CitH3 (ab281584, UK), anti-MPO (Elabscience, E-AB-70280, China), anti-NE (ab131260,UK), ,anti-NLRP3 (ab263899, UK), anti-LDH (Abmart, T55348, UK), anti-caspase-1 (Abmart, TA5418, China), anti-caspase-1 p20 (WL02996a, Abmart, China), anti-GSDMD (Abmart, TA4012, China), anti-ASC (Abmart, PA7120, China), anti–IL-1β (Abmart, TA5103, China), anti–lamin-B (Wanlei, 01775, China), and anti-GAPDH (Elabscience, E-AB-40337, China). After incubation with primary antibodies at 4 °C overnight, the membrane was washed with TBST buffer (TBS containing 0.1% Tween 20; Solarbio, T8220, China) and incubated for 1 h at room temperature with HRP-conjugated secondary antibodies: goat anti-rabbit IgG (E-AB-1003, China) or goat anti-mouse IgG (E-AB-1005, China). Protein bands were visualized using an enhanced chemiluminescence detection kit (Millipore, WBKLS0100, USA) [16]. Extraction of dsDNA from cell culture supernatant A volume of 120 µL of cell culture supernatant was collected. Genomic double-stranded DNA (dsDNA) was extracted using the Fast Pure Animal Tissue/Cell Genomic DNA Kit (Ecotop, EK-5312, China). The concentration of dsDNA was quantified with the Quant-iT™ PicoGreen™ dsDNA Assay Kit (Invitrogen, P7589, USA). Absorbance was measured using a multifunctional microplate reader (Biotech Synergy H1, USA) at excitation/emission wavelengths of 488 nm and 525 nm, respectively. Each sample was measured in three replicate wells, and the entire experiment was repeated six times independently. Detection of reactive oxygen species (ROS) and reactive nitrogen species (RNS) Neutrophils (1 × 10⁶ cells per group) were centrifuged at 400 × g for 5 min. ROS and RNS levels were detected using the ROS Detection Kit (ab139476, UK) and RNS Detection Kit (BestBio, BB-470567, China), respectively. Briefly, 10 µL of reaction solution was added to the cell pellet, gently mixed, and incubated at 37 °C under 5% CO₂ for 1 h (ROS) or 30 min (RNS). After five washes with buffer, cells were resuspended in HBSS. The FITC fluorescence signal was analyzed by flow cytometry. Microscopy Immunofluorescence Small round cover slips (14 mm diameter) were pre-treated with 1 × polylysine for 1 min. Neutrophils (2 × 105 cells/well) from each group were seeded onto the cover slips in a 24-well plate and cultured for 4 h at 37 °C with 5% CO₂. Cells were fixed with 4% paraformaldehyde for 15 min, and blocked with 5% BSA for 1 h. Primary antibodies—anti-PAD4 (ab128086, UK), anti-CitH3 (ab281584, UK), anti-NE (ab131260, UK), and anti-GSDMD-N’ (Abmart, TA4012, China)—were diluted 1:200 in 5% BSA and incubated with the samples overnight at 4 °C. After washing with TBS (Solarbio, T1080, China), secondary antibodies (goat anti-mouse Alexa Fluor 594, ab150120, UK; goat anti-rabbit Alexa Fluor 488, ab150077, UK) were applied at 1:1000 dilution for 1 h at room temperature. Nuclei were stained with DAPI (1:10,000; Sigma, D9542, USA) for 10 min. Coverslips were mounted with anti-fade mounting medium (VECTASHIELD, ZH0219, USA) and sealed with nail polish. Imaging was performed using an inverted fluorescence microscope (Nikon Eclipse Ti2-E, Japan) at 200 × magnification [16]. Transmission and scanning electron microscopy For TEM, samples were fixed with osmium tetroxide, dehydrated through an ethanol gradient, permeated with acetone, embedded in epoxy resin, and stained with 2% uranyl acetate and lead citrate for 15 min at room temperature. Observations were carried out using a Tecnai G20 TWIN microscope (USA). For SEM, samples were dehydrated and dried using the critical point drying method, then imaged with a LEO 1530VP microscope (Leica, Germany). Immunohistochemical staining Tissues including the oral mucosa, colon, and pericardial arteries and veins were collected from BALB/c mice across treatment groups for immunohistochemical analysis. Using anti-CitH3 antibody (1:200, ab281584, Abcam, UK) and anti-GSDMD-N’ antibody (1:100, TA4012, Abmart, China), standard procedures including antigen retrieval, blocking, primary antibody incubation at 4 °C overnight, HRP-conjugated Goat Anti-Rabbit IgG (H + L) (Beyotime, A0208, China) reaction at room temperature, and DAB development were performed to detect neutrophil extracellular traps (NETs) and pyroptosis-related protein expression. The results demonstrated that PEX168 inhibits the occurrence of NETosis and pyroptosis in multiple tissues [17]. Statistical analysis Data are expressed as mean ± standard deviation (SD) and analyzed using SPSS 25.0. One-way ANOVA was applied for group comparisons. When homogeneity of variance was confirmed, Tukey’s HSD test was used for overall analysis and Fisher’s LSD test for pairwise comparisons. In cases of heteroscedasticity, the Games-Howell procedure and Tamhane’s T2 method were employed for omnibus and post hoc testing, respectively. In animal experiments, after successful model verification, subjects were randomly assigned to model control or treatment groups. Healthy controls were included as a separate baseline group and did not undergo randomization. All drug administration, sample processing, and data analysis were performed under blinded conditions. A sample size of n ≥ 5 per group was chosen based on preliminary effect size estimates (Cohen’s d > 1.5) to ensure sufficient statistical power. A p-value < 0.05 was considered statistically significant. Results PEX168 reduces NETosis in BD patients Protein expression levels of PAD4, MPO, CitH3, NE, and LDH, as well as extracellular dsDNA content, were significantly elevated in neutrophils from BD patients (Fig. 1). In contrast, treatment with 6.4 ng/mL PEX168 markedly reduced the expression of these markers (P = 0.000). Following red blood cell lysis, neutrophil purity reached 88.75%, which increased to 96.58% after negative magnetic selection (Fig. 1C). ROS production was significantly higher in BD neutrophils (Fig. 1D) and decreased in a dose-dependent manner after PEX168 treatment (P = 0.002). The 6.4 ng/mL PEX168 group showed significantly lower ROS levels compared to the NC, BD, and 1.6 ng/mL PEX168 groups (P = 0.001). Intracellular RNS levels remained unchanged across all groups (P = 0.665). Ultrastructural analysis indicated that neutrophils from patients with BD showed several distinct features, including membrane ruffling, prominent pseudopodia, and cytoplasmic vacuolation. Additionally, there was evidence of mitochondrial swelling and lysosomal rupture. The chromatin within these cells appeared mottled, characterized by irregular condensation patterns. In comparison, BD neutrophils treated with LPS + 6.4 ng/mL PEX168 showed smoother membranes, reduced pseudopodia formation, fewer cytoplasmic vacuoles, and improved mitochondrial integrity (Fig. 2A). In the BD + 6.4 PEX168 group, chromatin, CitH3 and NE in neutrophils were predominantly retained intracellularly, in contrast to the BD group, where it was extruded extracellularly to form NETs. (Fig. 2B). Transmission electron micrographs and immunofluorescence images showing that PEX168 reduces NETosis and improves cellular integrity in neutrophils from BD patients. A BD neutrophils exhibited membrane ruffling, pseudopodia, cytoplasmic vacuolation, mitochondrial swelling, lysosomal rupture, and mottled chromatin. PEX168 (6.4 ng/mL) improved membrane smoothness, organelle integrity, and chromatin condensation. (Yellow arrows indicate chromatin; pink arrows indicate the nuclear membrane; blue arrows indicate mitochondria). B Chromatin, CitH3, and NE were predominantly retained intracellularly in the BD + 6.4 PEX168 group, contrasting with extracellular extrusion and NETs formation in the BD group. Values represent the mean ± SD. n = 6, *P < 0.05, **P < 0.01 PEX168 reduces LPS-induced NETosis in human neutrophils Treatment with LPS markedly induced neutrophil extracellular trap (NET) formation, as evidenced by elevated expression of neutrophil elastase (NE) and citrullinated histone H3 (CitH3). The administration of increasing concentrations of PEX168 significantly suppressed the LPS-induced upregulation of both NE and CitH3, demonstrating a dose-dependent inhibitory effect on NETosis. Notably, however, the addition of a low concentration of PEX168 (1.6 ng/mL) resulted in a significant increase in the expression of CitH3 and NE (Fig. 3A). PEX168 reduces LPS-induced NETosis in human neutrophils. A LPS increased CitH3 and NE, which were suppressed by high-dose PEX168 (6.4 ng/mL) but enhanced at 1.6 ng/mL. B LPS caused membrane ruffling, organelle damage, and chromatin condensation; PEX168 (6.4 ng/mL) improved ultrastructure. (Yellow arrows indicate chromatin; pink arrows indicate the nuclear membrane; blue arrows indicate mitochondria). C PEX168 reduced ROS dose-dependently (P = 0.005); RNS was unchanged (P = 0.062). D, E Extracellular CitH3, PAD4, and NE increased with LPS and decreased with 6.4 ng/mL PEX168; 1.6 ng/mL increased CitH3 and NE. Values represent the mean ± SD. n = 6, *P < 0.05,**P < 0.01 Morphological analysis revealed that LPS-stimulated neutrophils exhibited membrane ruffling, dense pseudopodia, cytoplasmic damage: including mitochondrial swelling, vacuolation, and lysosomal rupture, as well as mottled chromatin with heterochromatin–euchromatin intermixing. In contrast, cells treated with LPS plus 6.4 ng/mL PEX168 displayed smoother cellular contours, pseudopod retraction, reduced chromatin condensation (though nuclear lobulation was absent), fewer azurophilic vacuoles, and improved mitochondrial integrity. These observations suggest that PEX168 promotes cytoskeletal stabilization, chromatin decondensation, and organelle repair (Fig. 3B). PEX168 treatment also significantly reduced reactive oxygen species (ROS) production in a dose-dependent manner (P = 0.005), while no significant differences in reactive nitrogen species (RNS) levels were observed across groups (P = 0.062) (Fig. 3C). Furthermore, the excretion of CitH3, PAD4, and NE was significantly enhanced in LPS-treated neutrophils. This effect was markedly attenuated following treatment with 6.4 ng/mL PEX168. It is worth noting that the group treated with LPS + 1.6 ng/mL PEX168 also exhibited an increase in the extracellular levels of CitH3 and NE, further supporting the concentration-dependent regulatory role of PEX168 in NETosis (Fig. 3D and E). PEX168 suppresses NETosis in multiple tissues of BD mice PEX168 demonstrated a dose-dependent effect on neutrophil extracellular trap (NET) formation in BD mice. In the oral mucosa, injection of low-dose PEX168 (1 or 2 μg/kg) significantly increased the expression of CitH3, NE, and LDH. In contrast, administration of 8 μg/kg PEX168 resulted in a marked reduction in these markers (Fig. 4A). PEX168 Suppresses NETosis in Multiple Tissues of BD Mice. A Low-dose PEX168 (1–2 μg/kg) increased CitH3, NE, and LDH in oral mucosa; 8 μg/kg reduced them. B BD neutrophils showed chromatin aggregation, nuclear membrane defects, mitochondrial damage, and dilated rough endoplasmic reticulum. PEX168 (8 μg/kg) improved ultrastructure. (Yellow arrows indicate chromatin; pink arrows indicate the nuclear membrane; blue arrows indicate mitochondria; green arrows indicate the rough endoplasmic reticulum). C ROS was high in BD mice and reduced by 8 μg/kg PEX168 (P = 0.002); RNS was also decreased with all treatments (P = 0.03). Values represent the mean ± SD, n = 5. *P < 0.05, **P < 0.01 Ultrastructural analysis revealed extensive cellular damage in neutrophils of BD mice, including heterochromatin aggregation, nuclear membrane irregularities (thickening and folding), mitochondrial abnormalities (swelling, cristae fusion, megamitochondria formation, and vacuolization), and dilated rough endoplasmic reticulum (RER) with degranulation. The group treated with 1 μg/kg PEX168 showed no significant improvement compared to BD controls. However, treatment with 8 μg/kg PEX168 resulted in notable cellular recovery: reduced heterochromatin condensation, improved nuclear membrane integrity, decreased mitochondrial vacuolization and megamitochondria formation, and attenuated RER dilation, although some cristae fragmentation persisted (Fig. 4B). PEX168 also significantly modulated oxidative stress levels. ROS production was markedly elevated in BD mice but significantly reduced following treatment with 8 μg/kg PEX168 (P = 0.002). RNS levels were lower in all PEX168-treated groups compared to the BD group (P = 0.03), with no significant differences among the various PEX168 dosage groups (P = 0.711) (Fig. 4C). Tissue-specific responses to PEX168 were observed. In the oral mucosa, low concentrations of PEX168 (1 or 2 μg/kg) not only failed to reduce CitH3 and NE expression but even resulted in a slight increase. A more pronounced elevation in CitH3 and NE expression was observed in the intestinal tract (P = 0.006). In contrast, higher doses (4, and 8 μg/kg) significantly suppressed both markers in the oral mucosa. In the colon, NETosis markers were effectively inhibited at 4 and 8 μg/kg. However, at 12 μg/kg, CitH3 and NE expression increased significantly, exceeding levels in the BD group (P = 0.008) (Fig. 5A). Immunofluorescence Images and Immunohistochemical Diagrams Showing that PEX168 Suppresses NETosis in Multiple Tissues of BD mice. A, B NETosis markers were tissue- and dose-dependent: 4–8 μg/kg inhibited markers in oral and colon tissue; 12 μg/kg increased them in colon. Values represent the mean ± SD, n = 5. *P < 0.05,**P < 0.01 Notably, the 8 μg/kg dose of PEX168 resulted in the most substantial reduction in CitH3 expression, identifying it as the optimal concentration for attenuating NETosis in BD mice (Fig. 5A and B). PEX168 attenuates neutrophil hyperactivation through inflammasome regulation and cellular stabilization PEX168 demonstrated a concentration-dependent regulatory effect on neutrophil hyperactivation, consistent with its impact on oxidative stress, cellular ultrastructure, and NETosis observed in Sects. “PEX168 Reduces NETosis in BD Patients”, “PEX168 reduces LPS-induced NETosis in human neutrophils” and “PEX168 Suppresses NETosis in Multiple Tissues of BD Mice”. At a low concentration (0.8 and 1.6 ng/mL), PEX168 enhanced the Caspase-1 p20/pro-Caspase-1 ratio, ASC speck formation, and IL-1β expression (Fig. 6A, B), correlating with elevated ROS (as shown in Fig. 3C) and pronounced chromatin release. Conversely, higher concentrations of PEX168 suppressed these inflammasome markers and significantly reduced IL-1β secretion, aligning with decreased ROS production, restored mitochondrial integrity, and inhibition of NETosis. PEX168 regulates hyperactivation via inflammasome and cellular stabilization. A, B Low-dose PEX168 (0.8–1.6 ng/mL) enhanced Caspase-1 activation, ASC specks, and IL-1β; high dose suppressed them. C GSDMD-N’ e was unchanged (P = 0.283); no correlation with IL-1β. High-dose PEX168 inhibited chromatin release without altering nuclear GSDMD-N’, indicating pyroptosis-independent NETosis. Values represent the mean ± SD, n = 5. *P < 0.05, **P < 0.01 Notably, GSDMD-N′ expression remained unchanged across all groups (P = 0.283), and no correlation was found between GSDMD-N′ and IL-1β (P = 0.551). Immunofluorescence confirmed that LPS-induced chromatin release was inhibited by high-dose PEX168 without altering the nuclear localization of GSDMD-N′ (Fig. 6C), indicating that NETosis occurred independently of pyroptosis. These results collectively suggest that PEX168 modulates hyperactivation primarily through upstream inflammasome components (e.g., NLRP3 or ASC), influencing caspase-1 activation and IL-1β maturation while mitigating oxidative stress and preserving structural and genomic stability—consistent with the cellular improvements observed under electron microscopy. PEX168 alleviates pyroptosis and NETosis in BD mice via inflammasome suppression and cellular stabilization In BD mice, pyroptosis was confirmed through both molecular and ultrastructural evidence. Increased expression of pyroptosis markers (NLRP3, Caspase-4, ASC, GSDMD-N’ and IL-1β) and characteristic morphological changes, including cellular swelling, membrane blebbing, and organelle damage, were observed in multiple tissues (Fig. 7A, B). PEX168 treatment dose-dependently suppressed these markers, with 8 μg/kg demonstrating the strongest inhibition of GSDMD-N′ expression and cellular damage (Fig. 7A–C). These improvements align with earlier findings of 3.3 where PEX168 reduced ROS, preserved mitochondrial integrity, and diminished NETosis in BD mice, collectively indicating that PEX168 alleviates pyroptosis and promotes cellular stability. PEX168 alleviates pyroptosis and NETosis in BD mice. A–C Pyroptosis markers (NLRP3, Caspase-4, ASC, GSDMD-N′, IL-1β), cellular swelling and disruption of organelle structure were increased in BD mice and suppressed dose-dependently by PEX168, with 8 μg/kg being the most effective. (Yellow arrows indicate chromatin; pink arrows indicate the nuclear membrane; blue arrows indicate mitochondria in B). Values represent the mean ± SD, n = 5. *P < 0.05, **P < 0.01 Notably, a cell-type difference was observed: whether the neutrophils from BD patients or LPS-treated cells of healthy donors, PEX168 consistently suppressed NETosis and hyperactivation but did not induce pyroptosis, as GSDMD-N′ remained localized in nuclear and uncorrelated with IL-1β release, as shown in the results of 3.2 and 3.4. In contrast, pyroptosis did occur in BD mice and was robustly inhibited by PEX168. Figure 8 demonstrates that PEX168 directly inhibits neutrophil hyperactivation and NETosis through a dual mechanism (antioxidant + inflammasome pathway suppression). By preventing GSDMD-N' cleavage, it suppresses neutrophil pyroptosis, thereby disrupting the vicious inflammatory cycle in Behçet’s disease. PEX168 inhibits hyperactivation and NETosis via dual antioxidant and inflammasome suppression, prevents pyroptosis by blocking GSDMD-N′ cleavage, and disrupts the BD inflammatory cycle Thus, PEX168 exerts a protective, multi-mechanistic role across experimental models: it dampens hyperactivation and NETosis in human neutrophils and ameliorates both pyroptosis and NETosis in BD mice, highlighting its potential as a therapeutic agent for neutrophil-driven pathologies. Discussion Behçet’s disease (BD) is a systemic inflammatory vasculitis that affects multiple organs, and while its pathogenesis is not fully understood, it is closely linked to genetic factors, such as HLA-B51, and dysregulated innate immune responses [18, 19]. Neutrophil hyperactivation, particularly excessive formation of nNETs, is considered a central effector mechanism leading to endothelial injury and systemic inflammation [20, 21]. This study presents new evidence that PEX168, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), significantly reduces neutrophil hyperactivation and NETosis in both cellular and murine models of BD, suggesting its potential as a targeted therapeutic option. An innovative aspect of this research is the clear connection established between the antioxidative effects of PEX168 and its ability to regulate NETosis and inflammasome activation. Our results demonstrate that PEX168 markedly reduced ROS levels, consistent with established evidence that GLP-1 RAs suppress NADPH oxidase (NOX2) activity and mitigate mitochondrial-derived oxidative stress [13, 22]. The decrease in ROS was accompanied by alleviated mitochondrial swelling and improved ultrastructural integrity, supporting the role of PEX168 in maintaining mitochondrial membrane stability and preventing mitochondrial permeability transition pore (mPTP) overactivation—a critical mechanism connecting mitochondrial dysfunction and neutrophil pathology in BD is evident. Mitochondrial swelling plays a significant role in the pathogenesis of BD, as it indicates a failure in bioenergetics and an increase in oxidative stress. These factors are pivotal in triggering inflammatory responses, which in turn contribute to the systemic manifestations of BD [20, 23]. Furthermore, PEX168 treatment suppressed CitH3 expression and chromatin release, indicating effective inhibition of NETosis. Notably, while previous studies have reported pyroptosis in BD patient tissues and immune cells [24, 25], our experiments using LPS-stimulated human neutrophils and neutrophils from BD patients did not observe classical pyroptotic cell death. This discrepancy may be attributed to several factors: First, cell-type specificity—unlike monocytes or epithelial cells that readily undergo pyroptosis, neutrophils may favor alternative death pathways, such as NETosis, particularly in inflammatory conditions [26]. Second, the responses can be stimulus-specific; although LPS can activate inflammasome signaling, it might not provide the necessary signal strength or additional stimuli, like ATP, to induce full-length gasdermin D (GSDMD) cleavage and pyroptosis in neutrophils [27]. Third, there are technical considerations to take into account; the lack of GSDMD-N expression and the absence of plasma membrane rupture, suggest that the inflammasome activation we observed may represent a sub-lytic state. In this state, caspase-1 activation leads to the secretion of interleukin-1 beta (IL-1β) without pushing the cells into pyroptotic death [28]. Our data reveal a complex, dose-dependent relationship between PEX168 and IL-1β activation. At low concentrations (0.8–1.6 ng/mL), PEX168 enhanced caspase-1 cleavage and IL-1β secretion, suggesting a transient boost in inflammasome signaling, likely due to compensatory activation of NF-κB [29]. In contrast, higher concentrations suppressed both caspase-1 p20 and IL-1β expression, indicating effective inhibition of the NLRP3–ASC–caspase-1 axis. This suppression was accompanied by a marked reduction in reactive oxygen species (ROS) production and preservation of mitochondrial integrity, indicating that PEX168 mitigates oxidative stress—a key driver of NLRP3 inflammasome assembly and neutrophil hyperactivation [30, 31]. Furthermore, pretreatment with PEX168 attenuated pathological changes in cellular ultrastructure, including mitochondrial swelling and plasma membrane disruption, which are associated with excessive NETosis and IL-1β release [26]. Critically, neutrophil hyperactivation is closely linked to pyroptosis, as sustained inflammasome signaling and ROS overproduction promote gasdermin D cleavage and pyroptotic cell death, amplifying tissue damage in inflammatory environments [32]. By reducing hyperactivation and ROS, PEX168 indirectly restrains the upstream triggers of pyroptosis, even though it does not directly inhibit GSDMD cleavage. Notably, GSDMD-N′ expression remained unchanged and localized in the nucleus across all treatments, suggesting that PEX168 operates upstream of pyroptotic execution, such as at the level of NLRP3 or ASC, without triggering downstream gasdermin-mediated pore formation [27, 33]. By concurrently reducing ROS, stabilizing cellular morphology, and limiting IL-1β-driven inflammation, PEX168 effectively restrains neutrophil hyperactivation and suppresses the formation of NETs, thereby attenuating both pyroptotic and NETotic pathways [34]. This upstream targeting may represent a novel mechanism compared to traditional biologics that either directly inhibit IL-1β, such as anakinra, or broadly suppress immune responses, like corticosteroids [13, 35]. Low concentrations of PEX168 (1–2 μg/kg) may partially inhibit the inflammasome, but residual activity or compensatory pathways, such as NF-κB, could transiently enhance pro-IL-1β transcription, leading to a temporary increase in IL-1β. As the concentrations increased (8 μg/kg), PEX168 completely suppresses the inflammasome, significantly reducing mature IL-1β production. However, the reversal of the beneficial effects observed at a dosage of 12 μg/kg in BD may be due to several factors. First, at a dosage of 12 μg/kg, PEX168 could surpass the optimal receptor saturation threshold, resulting in unintended activation of alternative pathways. This may lead to compensatory pro-inflammatory signaling through unintended GPCR cross-talk or Fcγ receptor-mediated effects in immune cells. Secondly, the colon possesses a unique immune microenvironment characterized by a high density of resident macrophages and TLR-expressing epithelial cells. A high dose of PEX168 might disrupt the delicate balance of gut microbiota and immune homeostasis, triggering local surges in cytokines that could overactivate tissue-protective pathways. For instance, the overproduction of TGF-β may paradoxically induce smad7-mediated inflammation. Finally, the dose-dependent aggregation of PEX168 could result in immune complex deposition within mucosal tissues, which may activate complement pathways, such as C5a, or FcγRIII on neutrophils, leading to the release of neutrophil extracellular traps. Meanwhile, mitochondrial stress in epithelial cells due to metabolic overload could result in the overproduction of ROS and RNS. PEX168 is under investigation for BD due to its targeted mechanisms that extend beyond general anti-inflammatory effects [13]. It specifically modulates neutrophil hyperactivity—a central pathological feature of BD characterized by excessive NETosis and pyroptosis—through NOX2-dependent ROS reduction, and reduces inflammation by suppressing endothelial NF-κB/VCAM-1 activation via GLP-1R/cAMP signaling [11]. This targeted action contrasts with conventional immunosuppressants that broadly suppress immunity without selectively countering neutrophil dysregulation [11], and existing therapies such as colchicine, glucocorticoids, and TNF-α inhibitors, which are limited by incomplete efficacy, systemic toxicity, multisystem adverse effects, and high relapse rates after discontinuation. Colchicine reduces NETosis indirectly by inhibiting microtubule polymerization and neutrophil chemotaxis, but with nonspecific effects on other immune cells. Anti-IL-1 could block IL-1β-mediated NETosis, but does not degrade existing NETs; it is associated with infection risks. DNase cleaves extracellular DNA in NETs but lacks effects on protein components [13, 36, 37]. These findings position PEX168 as a promising candidate for clinical translation, particularly as it offers a favorable safety profile derived from extensive use in type 2 diabetes and may further mitigate vascular inflammation through GLP-1R/cAMP-dependent pathways [22, 35, 37], suggesting a superior risk–benefit ratio compared to potent off-label immunosuppressants. Moreover, PEX168, a GLP-1 analog, has the potential to normalize the dysregulation of the IL-17/IL-23 axis, as indicated by the suppression of Th17 cells observed with other GLP-1 receptor agonists in various autoimmune models [38]. However, the specific data regarding its effects in BD are currently lacking. Future clinical studies should evaluate its efficacy in reducing recurrent oral ulcers, uveitis, and vascular events in BD patients, particularly those refractory to current treatments. Cl-amidine is an irreversible inhibitor of PAD4 [39]. It permanently inactivates the enzyme by forming a covalent bond with the cysteine residue at the PAD4 active site. This agent acts on the core biochemical pathway of neutrophil extracellular trap formation, directly intervening in the processes of epigenetic modification and cell death. In contrast, PEX168, as a long-acting GLP-1R agonist, triggers the cAMP/PKA signaling pathway. It inhibits multiple pro-inflammatory signaling pathways that stimulate NET formation. This indirect suppression of NETosis is achieved by reducing the activity of NADPH oxidase, decreasing the production of ROS, and inhibiting pro-inflammatory transcription factors. PEX168 triggers anti-inflammatory and immunomodulatory pathways, thereby indirectly suppressing key pathological processes in Behçet’s disease. The potential mechanisms are as follows: it inhibits neutrophil overactivation, directly reducing damage to the vascular endothelium and alleviating mucocutaneous lesions. GLP-1 receptor agonists can suppress the differentiation of Th1 and Th17 cells while promoting the function of anti-inflammatory regulatory T cells, significantly reducing the levels of key pro-inflammatory cytokines, including TNF-α, IL-6, IL-1β, and IL-17, and inhibit appetite and reduce body weight, leading to a decrease in pro-inflammatory cytokines secreted by adipose tissue. This study has several limitations that should be acknowledged. First, the exact molecular target of PEX168 within the NLRP3 inflammasome or the NETosis machinery, such as the inhibition of PAD4, is not clearly defined [40]. Second, the translational relevance of the findings is limited due to the differences between murine models and human BD. It is important to explore potential interactions between PEX168 and standard BD treatments, including colchicine and anti–IL-1 agents, as this could have significant implications for therapy; and whether PEX168 directly interacts with other essential nodes involved in NETosis. Conclusion In conclusion, our comprehensive analyses indicate that PEX168 effectively reduces neutrophil hyperactivation, NETosis, and oxidative stress in experimental models of Behçet’s Disease (BD). This effect appears to be mediated through mechanisms that involve the suppression of reactive oxygen species (ROS) and the regulation of inflammasomes. These findings support the potential of GLP-1 receptor agonists (GLP-1 RAs) as a promising new therapeutic approach for BD and other inflammatory diseases driven by neutrophils. Acknowledgements The authors acknowledge Kun Wen and Ling Zeng for providing technical assistance. Abbreviations Behçet’s disease Polyethylene glycol loxenatide Transmission electron microscopy Scanning electron microscopy Double strain DNA Reactive oxygen species Reactive nitrogen species Peptidyl arginine deiminase 4 Myeloperoxidase Elastase Lactate-dehydrogenase NLR family pyrin domain containing 3 Gasdermin D Apoptosis-associated-speck-like-protein Histone H3 Lymphocyte antigen 6complex-locus g Lipopolysaccharide Glucagon-like peptide-1 receptor agonists Phosphate-buffered saline Negative control Diaminophenyl indole Author contributions JiaF: conceptualization, resources, methodology, software, investigation, formal analysis, writing—original draft, writing—review & editing. WuXL: data curation, investigation, formal analysis, validation, writing—original draft. ShengHY: resource, software, visualization. Funding This work was supported by the Basic and Applied Research Foundation of Guangdong [Grant No. 2020A1515110733] and the Stomatological Hospital of Southern Medical University Research Fund [Grant No. RC202006]. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013), and approved by the Laboratory Animal Ethics Committee of Southern Medical University's. All participants confirmed the information in this study and signed an informed consent form. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Fang Jia and Xiaoli Wu have contributed equally in this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.